title: Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
abstract: BACKGROUND
  The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the patients with BCLC stage B disease is heterogeneous showing different tumor statuses and Child-Pugh scores; treatment strategies other than TACE are frequently employed for the patients in this stage. Based on the subclassification system proposed by Bolondi et al. [Semin Liver Dis 2012;32:348-359], we developed the Kinki criteria focusing on a substaging for BCLC stage B disease, which is simpler and should be more suitable in actual clinical setting in Japan. In this study, we evaluated the performance of Kinki criteria.
  
  
  CONCLUSIONS
  This study included 1,633 HCC patients who received first-line treatment at the Kindai University Hospital. Patients were classified into subgroups based on the Kinki criteria and the survival time was estimated for each group. There were 156 (33.3%) patients in subclass B1, 278 (59.3%) in B2, and 35 (7.4%) in B3. The median overall survival times and 95% CI for BCLC B subclasses B1, B2, and B3 were 4.3 years (3.7-4.9), 2.9 years (2.2-3.4), and 1.1 years (0.5-1.8), respectively (p < 0.001). Key Messages: Classification of HCC patients in BCLC stage B based on the Kinki criteria showed statistically significant differences in survival, indicating the performance of Kinki criteria, which takes Child-Pugh score and tumor status into account for determining treatment options for HCC in BCLC stage B.
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arizumi
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Mina
authors.initials: M
authors.lastname: Iwanishi
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Minami
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Chishina
authors.forename: Masashi
authors.initials: M
authors.lastname: Kono
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitai
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Inoue
authors.forename: Norihisa
authors.initials: N
authors.lastname: Yada
authors.forename: Satoru
authors.initials: S
authors.lastname: Hagiwara
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Minami
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ida
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Sakurai
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kitano
authors.forename: Naoshi
authors.initials: N
authors.lastname: Nishida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000145:classification / Q000473:pathology* / Q000628:therapy; D016461:Chemoembolization, Therapeutic / Q000379:methods; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods; D006801:Humans; D007564:Japan; D008113:Liver Neoplasms / Q000145:classification / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D015203:Reproducibility of Results; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents